Biocon Ltd (BIOCON)

Biocon Chairperson Lauds Government's Research Investment Plans - 23 Jul, 2024

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics, praises the government's investment in research and innovation in various sectors as shown in Budget 2024. She also advocates for GST exemptions on all cancer drugs and diagnostics.

Kiran Mazumdar-Shaw Reacts to Karnataka's New Bill Mandating Reservation for Locals - 17 Jul, 2024

Biocon founder Kiran Mazumdar-Shaw has expressed caution over Karnataka's new bill that mandates reservation for locals in private firms. While it is an understandable move for job creation, she stressed on the importance of skilled talent and not impacting Karnataka's position as a leader in technology.

Biocon Ltd Drops for Fifth Straight Session - 12 Jul, 2024

Biocon Ltd's stock dropped by 1.1% to Rs 350.65 on the NSE, while the benchmark NIFTY rose by 0.98%. The company has gained around 3.7% in the last month and is a constituent of the Nifty Pharma index, which has increased by 3.77% in the same period.

Biocon Signs Licensing Agreement; Goes Ex-Dividend Soon - 01 Jul, 2024

Biocon signs an exclusive licensing and supply agreement with Handok for the commercialisation of Synthetic Liraglutide in South Korea. The company is also set to go ex-dividend soon, with analysts maintaining a Buy rating and a price target of Rs. 400/share.

Religare Broking Picks Biocon as Top Investment in Nifty 50 July Series - 30 Jun, 2024

Biocon has been identified by Religare Broking as a promising investment in the Nifty 50 July series due to the expected strong performance of the pharma sector. The stock gained 11% in price and added 19% OI in the June series.

Biocon Ltd's Earnings Rise Faster Than Most Companies - 29 Jun, 2024

Biocon Ltd has seen a 37% overall rise in EPS over the last three years, with estimates suggesting earnings will grow by 29% per annum over the next three years. Shareholders are optimistic about its future.

Biocon Shares Gain Interest from Investors - 28 Jun, 2024

Investors, including Midcap Mugul and Calculator fund, Emperor brokerage, and bureaucrats, are taking interest in Biocon shares. The bet is that a major success in its biosimilars pipeline could trigger a re-rating. However, the stock has not delivered meaningful returns for almost 8 years now.

Biocon Receives Approval for Biosimilar Manufacturing Facility - 25 Jun, 2024

Biocon Ltd's subsidiary, Biocon Biologics, has received approval from EMA to manufacture biosimilar Bevacizumab in its new facility. Kiran Mazumdar Shaw expresses excitement about Biocon's gain in market share for its biosimilars in the US.

Biocon Subsidiary Receives Approval for Biosimilar Manufacturing Facility - 24 Jun, 2024

Biocon's subsidiary, Biocon Biologics, has received European Medicines Agency (EMA) approval to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies drug substance facility in Bengaluru. The EMA also renewed the Good Manufacturing Practice certificates of compliance for Biocon's biosimilars manufacturing facility in Bengaluru and insulin facility in Malaysia.